WideCells Group

Private Investor Evening


WideCells Group PLC (‘WideCells Group’ or ‘the Group’)

Private Investor Evening and CFO Now Employed Fulltime

WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground-breaking insurance for stem cell treatment, is pleased to the confirm details of its upcoming Private Investor Event, to be held at 5.30pm on Wednesday 12 July 2017 at Shard Capital, 23rd floor, 20 Fenchurch St, London EC3M 3BY.  With revenues now being received and set to increase, CEO João Andrade will provide investors with an update on the Group’s recent milestone developments and outline future growth plans.   This will be followed by a Q&A session and refreshments.  For security reasons, investors are required to bring identification to the event, as this is needed to enter the building.  

To register for this event, please RSVP to ‘shareholderenquiries@stbridespartners.co.uk’ with ‘WideCells Investor Event’ in the subject line.

The Company is also pleased to announce that its Chief Financial Officer (‘CFO’) David Bridgland, who has previously been employed on a part-time basis, is now working with the Company full-time, effective 1 July 2017.  With revenues now being generated from two of the Group’s divisions – namely WideCells division, which is focussed on stem cell storage and research, and CellPlan Limited, which has recently launched in the UK its core stem cell insurance product CellPlan –  Mr Bridgland’s full-time appointment reflects WideCells Group’s increased operational presence.  Mr. Bridgland will be attending the upcoming Investor Evening and will be available for questions.

WideCells Group CEO, João Andrade, said “We are delighted that David will now be working with us on a full-time basis.  As CFO David has already proven invaluable in helping us build our Company into the revenue generative provider of stem cell services it is today and his move to a full-time position reflects our increased levels of activity and growing number of revenue streams.  I look forward to his greater involvement in the Company as we continue to rapidly grow our innovative business.  This is undoubtedly an exciting time for our Company and both David and myself look forward to meeting shareholders at our upcoming investor event on Wednesday 12 July 2017 as we provide an overview of recent corporate developments and outline our exciting plans for the future.”



For further information, please visit the Company’s website www.widecellsgroup.com, follow us on Twitter @WideCells_Group or contact:


WideCells Group

CEO – João Andrade

Tel:  +351 919 033 171

Smaller Company Capital Ltd

Broker – Jeremy Woodgate & Rupert Williams

Tel: +44 (0) 20 3651 2912

Shard Capital Partners LLP

Broker – Damon Heath & Erik Woolgar

Tel: +44 (0) 207 186 9950

St Brides Partners Ltd

PR – Charlotte Page & Olivia Vita

Tel: +44 (0) 20 7236 1177


Notes to Editors


WideCells Group PLC is building an integrated stem cell services company, focused on making stem cell treatments accessible and affordable.  In June 2017, the Group was ranked as the 21st most disruptive company globally by DISRUPT 100, an annual index celebrating the businesses with the most potential to influence, change or create new global markets.

With this in mind, it has created three divisions:

  • CellPlan: the world’s first stem cell healthcare insurance plan with financial cover for medical treatment, travel and accommodation expenses and concierge service to manage the treatment process
  • WideCells: the Institute of Stem Cell Technology has been established and is based in the University of Manchester Innovation Centre to focus on stem cell research and regenerative medicine. WideCells also has international cryogenics divisions specialising in stem cell storage.
  • WideAcademy: developing an education and training division to promote awareness of the benefits of stem cell storage across the global general practice community.

The Group has built an experienced senior management team that has been integral to the development of its growth and business to date.

Stem Cell Fast Facts:

  • Cord blood (which is taken from the umbilical cord) provides the most effective source of stem cells for families due to it being simple, safe and painless to collect relative to other sources of stem cells such as bone marrow – WideCells will focus on promoting the collection and storage of this.
  • Since 2005, there has been a 300% increase in the number of illnesses that can be treated using stem cells
  • 82 illnesses can currently be treated using stem cell procedures
  • Despite initial storage often costing no more than a few £thousand, actual treatment can cost in the £hundreds of thousands


WideCells Group PLC